Key terms
About MYNZ
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MYNZ news
Apr 25
9:31am ET
Mainz Biomed reports topline results from pooled study of mRNA biomarkers
Apr 24
6:59am ET
Mainz Biomed Announces Upcoming Annual Meeting
Apr 19
7:29am ET
Mainz Biomed Secures New Funding Agreement
Apr 12
6:20am ET
Analysts’ Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)
Mar 19
8:16am ET
Mainz Biomed to organize HALLO DOC! event
Mar 18
8:18am ET
Mainz Biomed to host educational webinar on Colorectal Cancer
Mar 12
8:36am ET
Mainz Biomed presents ColoAlert at UDH Congress 2024
Mar 06
11:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Iterum Therapeutics (ITRM), Mainz Biomed B.V. (MYNZ)
Mar 06
11:20am ET
Mainz Biomed price target lowered to $3 from $5 at H.C. Wainwright
Mar 05
8:25am ET
Mainz Biomed partners with Trusted Health Advisors
Feb 27
8:31am ET
Mainz Biomed to showcase ColoAlert at Gynecology Conference
Feb 22
8:05am ET
Mainz Biomed announces distribution partnership with Praxisdienst
Feb 21
8:12am ET
Mainz Biomed partners with TomaLab to expand availability of ColoAlert in Italy
Feb 06
8:22am ET
Mainz Biomed announces opening of EOL
No recent press releases are available for MYNZ
MYNZ Financials
Key terms
Ad Feedback
MYNZ Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MYNZ Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
